CRNX Quote, Financials, Valuation and Earnings

Gossamer Bio, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -362.73%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Gossamer Bio, Inc.'s return on equity of -615%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $84.08, signalling upside risk potential of 96.9%. On the other hand Gossamer Bio, Inc. has an analysts' consensus of $9.43 which suggests that it could grow by 311.73%. Given that Gossamer Bio, Inc. has higher upside potential than Crinetics Pharmaceuticals, Inc., analysts believe Gossamer Bio, Inc. is more attractive than Crinetics Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.195, which suggesting that the stock is 80.492% less volatile than S&P 500. In comparison Gossamer Bio, Inc. has a beta of 1.931, suggesting its more volatile than the S&P 500 by 93.136%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gossamer Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Gossamer Bio, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Gossamer Bio, Inc. quarterly revenues of $13.3M. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Gossamer Bio, Inc.'s net income of -$48.2M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Gossamer Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,591.22x versus 11.81x for Gossamer Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of --. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $84.08, signalling upside risk potential of 96.9%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1625.63%. Given that GT Biopharma, Inc. has higher upside potential than Crinetics Pharmaceuticals, Inc., analysts believe GT Biopharma, Inc. is more attractive than Crinetics Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.195, which suggesting that the stock is 80.492% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.887%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are larger than GT Biopharma, Inc. quarterly revenues of --. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,591.22x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -39.75%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $84.08, signalling upside risk potential of 96.9%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $671.07 which suggests that it could grow by 44.41%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.195, which suggesting that the stock is 80.492% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.010, suggesting its less volatile than the S&P 500 by 201.017%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,591.22x versus 13.92x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -586.58%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Sutro Biopharma, Inc.'s return on equity of -10195.04%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $84.08, signalling upside risk potential of 96.9%. On the other hand Sutro Biopharma, Inc. has an analysts' consensus of $21.25 which suggests that it could grow by 31.5%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Sutro Biopharma, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.195, which suggesting that the stock is 80.492% less volatile than S&P 500. In comparison Sutro Biopharma, Inc. has a beta of 1.546, suggesting its more volatile than the S&P 500 by 54.647%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sutro Biopharma, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Sutro Biopharma, Inc. quarterly revenues of $9.7M. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Sutro Biopharma, Inc.'s net income of -$56.9M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sutro Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,591.22x versus 4.14x for Sutro Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.